drugset / Trial / NCT06416852

Clinical Study of 18F-Alfatide Injection PET/CT

NCT06416852

Phase 3 Not yet recruiting 428 enrolled Yantai LNC Biotechnology Singapore PTE. LTD.
NaSingle-groupOpen-labelDiagnostic

Summary

This is a multicenter, open, non-inferiority Phase III clinical study to evaluate the efficacy of 18F-Alfatide Injection PET/CT compared with 18F-FDG PET/CT in the diagnosis of lymph node metastasis in non-small cell lung cancer. This trial will include 428 patients with non-small cell lung cancer confirmed by imaging, histopathology and/or cytology or highly suspected by investigators, suspected lymph node metastasis and proposed radical surgery and lymph node dissection. Eligible subjects will receive 18F-Alfatide Injection PET/CT and 18F-FDG PET/CT scans within 1 week. Subjects will undergo relevant security checks before and after each scan. The subjects underwent radical surgery and lymph node dissection within 2 weeks of completing both scans, and the obtained lymph nodes were pathologically examined as the gold standard to compare the diagnostic efficacy of 18F-Alfatide versus 18F-FDG for lymph node metastasis.

Timeline

Start
2024-08
Primary completion
2026-08
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-Alfatide Diagnostic / imaging agent 0.1 unknown Intravenous
Subject 18F-Alfatide Diagnostic / imaging agent 0.15 unknown Intravenous
Subject 18F-FDG Diagnostic / imaging agent 5 unknown Intravenous
Subject 18F-FDG Diagnostic / imaging agent 10 unknown Intravenous